

## Intracellular ROS-scavenging nanozymes for the treatment of osteoarthritis

Jessica L. Aldrich<sup>1</sup>, Gengfu Dong<sup>1</sup>, Arjun Panicker<sup>1</sup>, Tomas Gayoso<sup>1</sup>, Jennifer Russell<sup>1</sup>, Kyle D. Allen<sup>1</sup>, Terence Ryan<sup>1</sup>, Blanka Sharma<sup>1</sup>


<sup>1</sup>University of Florida, Gainesville, FL

[Jessica.aldrich@ufl.edu](mailto:Jessica.aldrich@ufl.edu)

**Disclosures:** Jessica Aldrich (N), Gengfu Dong (N), Arjun Panicker (N), Tomas Gayoso (N), Jennifer Russell (N), Kyle Allen (editor - OAC), Terence Ryan (N), Blanka Sharma (42Bio),

**INTRODUCTION:** Nanozymes, antioxidant-mimicking nanoscale biomaterials, are an emerging therapeutic strategy in medical applications related to oxidative stress. These nanomaterials can be engineered to mimic endogenous enzymes, such as catalase or superoxide dismutase, or can directly scavenge excess reactive oxygen species (ROS) that contribute to the progression of oxidative stress. Oxidative stress plays a central role in the development of osteoarthritis, however it remains an elusive therapeutic target – conventional small molecule antioxidants and natural enzymes have been limited by poor retention and localization to the osteoarthritic (OA) joint. In contrast, nanozymes can be engineered with properties that confer better stability and bioavailability than existing antioxidant therapies<sup>1</sup>. One example includes manganese dioxide nanoparticles (MnO<sub>2</sub> NPs), which our group has engineered with properties favorable for cartilage localization and chondrocyte uptake, and consequently chondroprotection upon oxidative stress induction<sup>2</sup>. However, there is little understanding of the molecular mechanisms and compartment specific functions of MnO<sub>2</sub>, or other nanozymes currently evaluated as potential OA

therapies. The objective of this work was to evaluate the uptake mechanisms and intracellular localization of MnO<sub>2</sub> NPs in human OA chondrocytes and determine the compartment specific ROS scavenging activity of MnO<sub>2</sub> NPs.




**Fig 1.** Figure 1. A) MnO<sub>2</sub> uptake into human OA chondrocytes is temperature is dose dependent, but uptake is measurable at both 4C and 37C indicating both active and passive uptake mechanisms can be used. B) Following uptake, MnO<sub>2</sub> moderately colocalizes with both lysosomes and mitochondria.

either the mitochondrial matrix, mitochondrial intermembrane space, or cytosol, were used to determine compartment specific H<sub>2</sub>O<sub>2</sub> scavenging ability of the MnO<sub>2</sub> NPs. Statistical analysis was conducted on GraphPad PRISM 10.2 whereby error bars indicate standard deviations and statistical comparison of means were conducted in GraphPad *via* a Dunnett's test or one-way ANOVA with Tukey's multiple comparisons tests.

**RESULTS:** MnO<sub>2</sub> NPs were visualized within human and bovine chondrocytes. Uptake was dose dependent, with increasing mean fluorescent intensity from 5 to 20 µg/mL, without impacting viability. While uptake was greater at 37°C compared with 4°C, there was measurable uptake at both temperatures, suggesting that MnO<sub>2</sub> utilized both active and passive routes of uptake (Fig 1A). There is no significant difference in MnO<sub>2</sub> NP uptake between male and female donors, based on mean fluorescent intensity. Intracellularly, MnO<sub>2</sub> colocalized to mitochondria and lysosomes, indicated by 0.6 and 0.4 Pearson correlation coefficients, respectively (Fig 1B). Results from the HyPer7 probes (Hyper 7 ratio) showed that MnO<sub>2</sub> NPs reduced H<sub>2</sub>O<sub>2</sub> levels in all three cellular compartments evaluated, with dose dependence noted in the mitochondrial matrix and intermembrane space. The thiol reducing agent dithiothreitol (DTT), was used to reverse the HyPer7 oxidation, acting as a positive control to confirm cell response returns to baseline.

**DISCUSSION:** MnO<sub>2</sub> NPs have a unique ability to enter chondrocytes and scavenge ROS in multiple cellular compartments. MnO<sub>2</sub> NPs enter chondrocytes through both passive and active transport mechanisms, rendering them available for localization to the cytosol and mitochondria. Colocalization and function of MnO<sub>2</sub> within the mitochondria may be driven by the electrostatic interaction between the cationic MnO<sub>2</sub> and the negatively charged mitochondrial matrix. Mitochondria are responsible for generating a significant amount of ROS within the cell and colocalization of MnO<sub>2</sub> may support endogenous antioxidant function, such as MnSOD (superoxide dismutase), or directly scavenging H<sub>2</sub>O<sub>2</sub> produced by the mitochondria. This is the first mechanistic analysis of the redox activity of MnO<sub>2</sub> NPs in chondrocytes. The limited molecular tools to measure ROS has impeded the progress in antioxidant therapies. The HyPer7 probes have been introduced into the field 17 years ago and have been used with other cell types, but this is the first instance of their use in chondrocytes, further expanding their application potential. MnO<sub>2</sub> scavenging is dose dependent, with a lower HyPer7 ratio in cells treated with 20 µg/ml MnO<sub>2</sub> before the addition of exogenous H<sub>2</sub>O<sub>2</sub> in all compartments except for the cytosol. This may indicate that there is a saturation effect of MnO<sub>2</sub> on H<sub>2</sub>O<sub>2</sub> in the cytosol. Comparatively, scavenging H<sub>2</sub>O<sub>2</sub> in the mitochondria may support overall cellular function and redox homeostasis, as suggested in our previous reports of the downstream effects of MnO<sub>2</sub> NPs. Advancing our understanding of how these nanomaterials deliver a therapeutic response is important for continuing to find treatments for stopping or slowing OA progression.



**Fig 2.** MnO<sub>2</sub> scavenges H<sub>2</sub>O<sub>2</sub> from the A) mitochondrial matrix, B) intermembrane space, C) and cytosol in a dose dependent manner. The HyPer7 ratio is decreased in the presence of MnO<sub>2</sub> at all timepoints following the addition of exogenous H<sub>2</sub>O<sub>2</sub>.

### SIGNIFICANCE/CLINICAL RELEVANCE:

Nanozymes such as MnO<sub>2</sub> are emerging technologies for effectively targeting oxidative in the treatment of numerous diseases including OA. This study is the first to interrogate the uptake and ROS scavenging mechanisms of MnO<sub>2</sub> NPs in chondrocytes, which will be important for further development and translation of this promising therapeutic strategy.

**ACKNOWLEDGEMENTS:** This material is based upon work supported by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) R01AR071335, R01AR080687; and F31AR083291.

**REFERENCES:** [1] Aldrich, J., et al., 2023 [2] Kumar, S., et al. 2019 [3] Pak, V., 2020